In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of ...
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers ...
SAN FRANCISCO and SUZHOU, China, May 19, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the ...
Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL). Preliminary ...
SHANGHAI--(BUSINESS WIRE)--Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it will present a Trials in Progress poster presentation at ...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company ...
SAN FRANCISCO and SUZHOU, China, Nov. 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, a clinical-stage biotechnology company focused on drugging the human immune synapse, today announced the publication of extensive data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback